Myriad Genetics (MYGN) executive compensation, 2026 proxy

Samraat S. Raha, President and Chief Executive Officer, was paid $5.7M in 2025, up 30% from $4.4M the year before. The CEO-to-median-employee pay ratio was 60:1, on median employee pay of $97,407.

Filed
April 14, 2026
Annual meeting
June 4, 2026
Pay year
2025
Named executives
8
CEO total pay
$5.7M+30% vs prior year
CEO to median employee
60:1median $97,407
CEO pay in equity
70%$4M in awards
Prior say-on-pay support
92%of votes cast
CEO Target Bonus
$920,000Short-term cash incentive target
Total Revenue
$824.5MFull-year 2025 revenue
Adjusted EBITDA
$38.9MFull-year 2025 adjusted EBITDA
Total Employees
2,675Employee population at year-end

How Raha was paid

$5.7M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary15%Stock awards70%Non-equity incentive14%All other compensation0%

Named executive officers

ExecutiveTotal
Samraat S. RahaPresident and Chief Executive Officer$5,686,740
Paul J. DiazFormer President and Chief Executive Officer$688,637
Benjamin R. WheelerChief Financial Officer$1,507,897
Scott J. LefflerFormer Chief Financial Officer$2,736,493
Mark S. VerrattiChief Operating Officer$3,145,251
Brian J. DonnellyChief Commercial Officer$6,000,145
Dale Muzzey, Ph.D.Chief Scientific Officer$1,862,912
Margaret AnconaFormer EVP, Strategy and Transformation$1,895,166

What changed and why

  • Samraat S. Raha succeeded Paul J. Diaz as President and Chief Executive Officer on April 30, 2025.
  • $5.7MSamraat S. Raha received total compensation of $5,686,740 for fiscal year 2025.
  • 92%Stockholders approved the executive compensation program with 92% support at the prior annual meeting.
  • $450KBrian J. Donnelly joined the company as Chief Commercial Officer with a sign-on bonus of $450,000.
  • 50%Executive compensation program grants 50% of equity in performance-based stock units subject to objective metrics.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.